Copyright
        ©The Author(s) 2021.
    
    
        World J Hepatol. Dec 27, 2021; 13(12): 1816-1827
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1816
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1816
            Table 1 Summarizes the literature on the co-existing prevalence of irritable bowel syndrome and non-alcoholic fatty liver disease to date
        
    | Author | Population studied | Study design | No. patients | Criteria for IBS diagnosis | IBS subtypes | Criteria for NAFLD diagnosis | Prevalence of NAFLD in IBS/ IBS in NAFLD | Outcomes | 
| Hasanain et al[15] | IBS | Cross sectional study | 100 patients with IBS | Rome III | IBS-C: 45%; IBS-D: 23%; IBS-M: 32%, | Ultrasound; No history of alcohol exposure; No exposure to steatogenic medications; Negative viral screen | 74% of those with IBS had co-existing NAFLD | Moderate/severe NAFLD significantly associated with moderate/severe IBS (OR: 2.4, 95%CI: 1.3-62.7, P = 0.026) | 
| Shin et al[16] | Healthy individuals via NHANES | Cross sectional study | 2345 patients with IBS | Rome IV | IBS-C: 1023; IBS-D: 1322 | Raised ALT or AST; Absence of excessive alcohol; Negative viral hepatitis screen | Prevalence of NAFLD in IBS-D: 12.9% (95%CI: 9.8-15.9); IBS-C: 9.0% (95%CI: 7.0-11.0) | NAFLD associated with diarrhoea vs normal bowel pattern (OR: 1.340, 95%CI: 1.007-1.784) and constipation (OR: 1.445, 95%CI: 1.028-2.031) | 
| Arasteh et al[17] | IBS | Cohort study | 1067 patients with IBS | Rome IV | IBS-D: 57 (5.3%); IBS-C: 380 (35.6%); IBS-U: 630 (59%) | Not documented | 3.7% | Liver disease not associated with IBS (Coefficient: 0.26, OR: 1.30, 95%CI: 0.92-1.82) | 
| Lee et al[19] | IBS vs control | Retrospective, cross sectional, case control study | 83 IBS patients; 260 age and sex matched control | Rome III | IBS-C: 14.8%; IBS-D: 49.4%; IBS-M: 31.3%; IBS-U: 4.5% | Investigated raised ALT, GGT, AST and features of metabolic syndrome | 16.9% of IBS patients had raised ALT; 24.1% had raised GGT | Significantly higher ALT in patients with IBS (16.9% vs 7.7%; P = 0.015); Significantly higher GGT in patients with IBS (24.1% vs 11.5%; P = 0.037); Significantly higher prevalence of metabolic syndrome in patients with IBS (32.5% vs 12.7%; P < 0.001) | 
| Sarmini et al[73] | IBS vs control | Observational study | 637942 | Clinical diagnosis | Not documented | Not documented | Not available | Patients with IBS significantly more likely to develop NAFLD compared to non-IBS group (OR: 3.204, 95%CI: 3.130-3.279, P < 0.001) | 
| Singh et al[24] | NAFLD | Retrospective analysis | 632 | Clinical diagnosis | Not documented | Ultrasound; Alcohol consumption < 20 g/d; Normal aetiological liver screen | 186 (29.4%) patients with NAFLD had clinical diagnosis of IBS | IBS symptoms are highly prevalent in those with NAFLD | 
| Jones-Pauley et al[22] | NAFLD | Cross-sectional study | 130 | Rome IV | Not documented | Not documented | 38 (29.2%) patients with NAFLD met Rome IV IBS criteria | High prevalence of IBS in patients with NAFLD; Significant increase in prevalence of depression (18.4% vs 5.4%, P = 0.01) and anxiety (31.6% vs 9.8%, P = 0.002) in those with co-existing IBS compared to those with NAFLD without IBS | 
- Citation: Purssell H, Whorwell PJ, Athwal VS, Vasant DH. Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence? World J Hepatol 2021; 13(12): 1816-1827
- URL: https://www.wjgnet.com/1948-5182/full/v13/i12/1816.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i12.1816

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        